Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

PHASE2RECRUITING

This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.

info
Simpliy with AI

Study details:

This is a phase 2, multicenter study to assess the safety, tolerability, CNS effects, pharmacokinetics, pharmacodynamics and clinical efficacy of SPG302 in adult participants with mild-to-moderate AD. The study will consist of 2 parts:. Part A: Placebo-controlled, randomized, safety and preliminary efficacy cohort with daily dosing for 28 day cycles.

Part B: a randomized expansion cohort of daily dosing for 28 day cycles.

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Age 45-85
  • Diagnosis of mild to moderate AD
  • Clinical laboratory values within normal range or < 1.5 times ULN
  • If receiving AD-specific treatment, have been on stable dose for ≥ 3 months prior to first dose of study drug.
  • Life expectancy of >2 years
  • Able and willing to provide written informed consent
  • Exclusion criteria

  • Any physical or psychological condition that prohibits study completion
  • Known cardiac disease
  • Active or history of malignancy in the past 5 years
  • Serious infection that will not be resolved by first day of study intervention.
  • History of clinically significant CNS event or diagnosis in the past 5 years.
  • Acute illness within 30 days of Day 1
  • History of suicidal behavior or suicidal ideation
  • History of chronic alcohol use or substance abuse in the last 5 years
  • HIV, hepatitis B and/or hepatitis C positive
  • Vaccines within 14 days
  • Receipt of investigational products within 30 days
  • Blood donation within 30 days
  • Pregnant or breastfeeding
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 45 and older

    Healthy volunteers accepted : No

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2024-07-29

    Primary completion: 2025-12-01

    Study completion finish: 2026-06-01

    study type

    Study type

    TREATMENT

    phase

    Phase

      PHASE2

    trial

    Trial ID

    NCT06427668

    Intervention or treatment

    DRUG: SPG302

    DRUG: Placebo

    Conditions

    • Alzheimer Disease

    Find a site

    Closest Location:

    St Vincent's Hospital

    Research sites nearby

    Select from list below to view details:

    • St Vincent's Hospital

      Sydney, New South Wales, Australia

    • Flinders Medical center

      Adelaide, South Australia, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    ACTIVE_COMPARATOR: Part A: Active SPG302 to be administered to adult participants with AD
    • Cohort 1: 12 participants with Alzheimer's Disease will be randomized in a 2:1 ratio to receive SPG302 or placebo. Study intervention will be 300 mg orally once daily for 28 days (cycle 1). All participants will receive open-label SPG302 for cycles 2-7. This arm may be expanded to cohort 2: 12 additional participants pending review of data, for additional dose exploration.
    DRUG: SPG302
    • synthetic small molecule
    PLACEBO_COMPARATOR: Part A: Placebo comparator to be administered to adult participants with AD
    • Cohort 1: 12 participants with Alzheimer's Disease will be randomized in a 2:1 ratio to receive SPG302 or placebo. Study intervention will be placebo capsule orally daily for 28 days (cycle 1). All participants will receive open-label SPG302 for cycles 2-7. This arm may be expanded to 12 additional participants as cohort 2 pending review of data, for additional dose exploration.
    DRUG: Placebo
    • Placebo
    EXPERIMENTAL: Part B: Expansion Cohort
    • Dose to be used and size of dosing cohort to be determined by Data Safety and Monitoring Committee following completion of Part A.
    DRUG: SPG302
    • synthetic small molecule

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    Change in Electroencephalogram (EEG) at resting state and at auditory evoked P300 from baseline to endpointElectroencephalogram (EEG) will provide non-invasive measurement of brain activity. This test will be used to measure resting state cognitive activity as well as cognitive activity after auditory stimulation. Sound stimuli is 500Hz and 2000Hz.8 months
    Change in Alzheimer's Disease Assessment Scale-Cog (ADAS-COG) total score from baseline to endpointThe Alzheimer's Disease Assessment Scale-Cognitive Subscale test (ADAS-Cog) measures language and memory, focusing on cognitive and non-cognitive functioning. It evaluates word recall, naming of objects, word recognition, comprehension and word finding. The ADAS-COG is scored 0-70. The higher the score the greater the impairment.8 months
    Change in Mini-Mental State Examination (MMSE) from baseline to endpointThe Mini-Mental State Exam (MMSE) is a test of cognitive function. It includes tests of orientation, attention, memory, language and visual-spatial skills. The lower the score the greater the impairment.8 months
    C-SSRS (Columbia Suicide Severity Rating Scale)Prospective suicidality assessment is performed using the Columbia-Suicide Severity Rating Scale (C-SSRS), a questionnaire to evaluate suicidal ideation and behavior. Answer "yes" on item 4 or 5 of the Suicidal Ideation section or "yes" on any item of the Suicidal Behavior section is considered positive. The suicidal behavior lethality sub-scale inquires about the level of actual or potential medical damage.8 months
    Change in Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS - CGIC) from baseline to endpointThe Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS - CGIC) is a metric for clinical assessment of symptom severity. It consists of 2 parts. First a baseline evaluation of patient and caregiver is performed to collect necessary clinical information. The clinician will then conduct the second phase of the assessment after a specified time period, and changes in symptom severity are indicated on a seven point scale. A higher scale indicates a worsening of symptoms.8 months
    Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale from baseline to endpointThe Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale is an scale that assesses the performance of daily tasks and activities. A lower score indicates lower functional performance.8 months
    Quality of Life in Alzheimer's Disease (QOL-AD) from baseline to endpointThe Quality of Life in Alzheimer's Disease (QOL-AD) is a test to evaluate the quality of life through a series of questions of ability to complete daily activities and tasks. A lower score indicates lower functional quality of life.8 months

    Secondary outcome

    Secondary Outcome MeasureSecondary Outcome DescriptionSecondary Outcome Time Frame
    Safety and tolerability of SPG302Incidence, nature and severity of adverse events (AEs) and serious adverse events (SAEs)8 months
    Plasma pharmacokinetics of SPG302 in participants with AD-Maximum Plasma Concentration (Cmax)Blood will be collected following administration of SPG302 and plasma levels will be evaluated to measure the maximum concentration.8 months
    Change in biomarkers in participants with AD from baseline to endpoint.To assess the effect of SPG302 on Neurofilament light (NfL), a protein elevated in AD. This will be measured in picometers/milliliter.8 months

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

    Other trails to consider

    Top searched conditions